Topic: Mental Health Research Network
Conditions
Interventions
Current interventions as of 03/05/2017:
A two arm single blind randomised superiority trial comparing a new generation computerised cognitive remediation programme (CIRCuiTS) plus trea
Sponsors
South London and Maudsley NHS Trust (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Participants will be entered into the study if they have: 1. A diagnosis of schizophrenia 2. Have been in touch with the mental health services for at least one year 3. Aged between 17 and 65 years old, either sex 4. Have a known cognitive deficit (poor performance in memory [digit span] and/or cognitive flexibility [WCST or Hayling Sentence Completion Test] in addition to poor social functioning [score of 2 or more on Social Behaviour Schedule])
Exclusion criteria
Exclusion criteria: 1. Plan to change their medication during the therapy phase of the study 2. Known substance dependence 3. Evidence of an organic cause to their cognitive difficulties (e.g. history of head injury)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Current primary outcome measures as of 03/05/2017: 1. Verbal working memory is assessed using Digit Span a working memory task at baseline, 12 weeks, and 26 weeks 2. Visual memory is assessed using the Rey Osterreith Complex Figure, a visual memory test at baseline, 12 weeks, and 26 weeks 3. Verbal executive function is assessed using the Hayling Sentence Completion test, measuring response inhibition at baseline, 12 weeks, and 26 weeks 4. Visual executive function was assessed using the Wisconsin Card Sorting Test, testing abstraction and cognitive flexibility at baseline, 12 weeks, and 26 weeks Previous primary outcome measures: Cognitive test battery, measured at timepoint 1 (0 weeks), 2 (12 weeks) and 3 (26 weeks) | — |
Secondary
| Measure | Time frame |
|---|---|
| Current secondary outcome measures as of 03/05/2017: 1. Community functioning is assessed using the Time Use Survey (a semi-structured interview recording participants’ time use, selected to capture widely disparate clinically meaningful increases in functional activity at baseline, 12 weeks, and 26 weeks 2. Symptoms are assessed using the Positive and Negative Syndrome Scale at baseline, 12 weeks, and 26 weeks Previous secondary outcome measures: 1. Community functioning, measured at timepoint 1, 2 and 3 2. Psychiatric symptoms, measured at timepoint 1, 2 and 3 | — |
Countries
United Kingdom
Outcome results
None listed